Department of Hepatopancreatobiliary Surgery, The Affiliated Hospital of Qinghai University, Xining, China.
Qinghai Province Key Laboratory of Hydatid Disease Research, Xining, China.
BMC Med Imaging. 2022 Feb 12;22(1):27. doi: 10.1186/s12880-022-00752-2.
Microwave ablation (MWA) is a popular therapy for liver malignant tumor in recent years. Few studies have been conducted on its use in the treatment of hepatic alveolar echinococcosis (HAE). The study aims to evaluate the efficacy and safety of MWA in the treatment of HAE.
This study analyzed the data of 45 patients (mean age, 38 ± 2 years; 24 males) diagnosed with HAE and underwent MWA treatment between June 2014 to December 2019. The patients after MWA were examined by CT or MRI [follow-up: 32 months (IQR 23-48.5)] to determine whether the lesions were relapsed and to evaluate the therapeutic effect of MWA. The safety of MWA was evaluated by monitoring postoperative complications. Clinical data, such as patient demographics, imaging features of the lesions, relevant findings of laboratory tests before and after ablation, and information related to ablation, were collected and analyzed. Paired-sample t tests and paired-sample Wilcoxon signed-rank tests were used to compare relevant laboratory indicators before and after MWA.
MWA was applied to 57 HAE lesions in 45 patients. The median size of lesions was 3.42 cm (IQR2.85-4.41). The rate of complete ablation was 100% (57/57). The median follow-up time was 32 months (IQR 23-48.5). The recurrence rate was 13% (6/45), and the median time of recurrence was 22 months. The rate of minor complications was 11.1% (5/45), and there were no major complications and deaths. Compared to preoperative, ALB, RBC, HBG, and PLT were decreased (p < 0.001); ALT, TB, DB, and WBC were increased (p < 0.001); and no statistically difference in PT, APTT, and INR (p > 0.05).
MWA might be a safe and effective way to cure HAE. Meanwhile, it provides a new option and a new way of thinking about treatment for patients with HAE.
微波消融（MWA）是近年来治疗肝脏恶性肿瘤的一种流行疗法。关于其在肝泡型包虫病（HAE）治疗中的应用，研究甚少。本研究旨在评估 MWA 治疗 HAE 的疗效和安全性。
本研究分析了 2014 年 6 月至 2019 年 12 月期间接受 MWA 治疗的 45 例 HAE 患者（平均年龄 38±2 岁；24 例男性）的数据。MWA 治疗后，通过 CT 或 MRI 进行检查[随访：32 个月（IQR 23-48.5）]，以确定病变是否复发，并评估 MWA 的治疗效果。通过监测术后并发症评估 MWA 的安全性。收集并分析患者人口统计学、病变的影像学特征、消融前后相关实验室检查结果以及与消融相关的信息等临床数据。采用配对样本 t 检验和配对样本 Wilcoxon 符号秩检验比较 MWA 前后相关实验室指标。
45 例患者的 57 个 HAE 病变接受了 MWA 治疗。病变的中位数大小为 3.42cm（IQR 2.85-4.41）。完全消融率为 100%（57/57）。中位随访时间为 32 个月（IQR 23-48.5）。复发率为 13%（6/45），中位复发时间为 22 个月。轻微并发症发生率为 11.1%（5/45），无严重并发症和死亡。与术前相比，ALB、RBC、HBG 和 PLT 降低（p<0.001）；ALT、TB、DB 和 WBC 升高（p<0.001）；PT、APTT 和 INR 无统计学差异（p>0.05）。
MWA 可能是治疗 HAE 的一种安全有效的方法。同时，它为 HAE 患者的治疗提供了一种新的选择和新的思路。
